Header Logo

Connection

Idoroenyi Amanam to Drug Resistance, Neoplasm

Back to Details
This is a "connection" page, showing publications Idoroenyi Amanam has written about Drug Resistance, Neoplasm.
Idoroenyi Amanam
Connection Strength
0.137
Drug Resistance, Neoplasm
  1. The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. Future Oncol. 2018 Aug; 14(19):1897-1908.
    View in: PubMed
    Score: 0.137
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.